Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial

Astrid Drivsholm Sloth, Michael Rahbek Schmidt, Kim Munk, Morten Schmidt, Lars Pedersen, Henrik Toft Sørensen, Hans Erik Bøtker, CONDI Investigators, M Bøttcher, A K Kaltoft, C J Terkelsen, N H Andersen, T M Hansen, S Trautner, J F Lassen, E H Christiansen, L R Krusell, S D Kristensen, L Thuesen, S S Nielsen, M Rehling, T T Nielsen, Astrid Drivsholm Sloth, Michael Rahbek Schmidt, Kim Munk, Morten Schmidt, Lars Pedersen, Henrik Toft Sørensen, Hans Erik Bøtker, CONDI Investigators, M Bøttcher, A K Kaltoft, C J Terkelsen, N H Andersen, T M Hansen, S Trautner, J F Lassen, E H Christiansen, L R Krusell, S D Kristensen, L Thuesen, S S Nielsen, M Rehling, T T Nielsen

Abstract

Objectives: Remote ischaemic conditioning (RIC) promotes cardioprotection in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-elevation myocardial infarction (STEMI). The effect of RIC may be modified by cardiovascular risk factors and their medications. We examined whether cardiovascular risk factors, lipid and glucose levels, and medication use influenced the efficacy of RIC in patients with STEMI treated with pPCI.

Design: Post hoc subgroup analysis of a single-centre randomised controlled trial.

Participants: A total of 139 patients with STEMI, randomised during ambulance transport to hospital for pPCI with (n=71) or without (n=68) RIC, met the trial criteria and achieved data for a myocardial salvage index (MSI).

Interventions: RIC was administered through intermittent arm ischaemia with four cycles of 5 min inflation and 5 min deflation of a blood pressure cuff.

Primary outcome measures: MSI, estimated by single-photon emission CT. We evaluated the efficacy of RIC on the MSI in patient subgroups of cardiovascular risk factors, lipid and glucose levels, and medication use.

Results: We found no significant difference in the efficacy of RIC in subgroups of cardiovascular risk factors, lipid and glucose levels, and medication use. However, point estimates indicated a reduced effect of RIC among smokers (median difference in MSI between RIC and control groups: -0.02 (95% CI -0.32 to 0.28) in smokers vs 0.25 (95% CI 0.08 to 0.42) in non-smokers, p value for interaction=0.13) and an increased effect of RIC in statin users (median difference in MSI between RIC and control groups: 0.34 (95% CI 0.03 to 0.65) in statin users vs 0.09 (95% CI -0.11 to 0.29) in non-statin users, p value for interaction=0.19).

Conclusions: RIC as an adjunct to pPCI seems to improve MSI in our trial population of patients with STEMI regardless of most cardiovascular risk factors and their medications. Our post hoc finding on a limited sample size calls for further investigation in large-scale multicentre trials.

Trial registration number: NCT00435266.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Study flow chart. Grey boxes represent study population eligible for stratified analysis (n=139). AAR, area-at-risk; ARBs, angiotensin II receptor blockers; FIS, final infarct size; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; MSI, myocardial salvage index; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning; STEMI, ST-elevation myocardial infarction.
Figure 2
Figure 2
Stratum-specific median differences in MSI between RIC and control groups according to cardiovascular risk factors, lipid and glucose levels, and medication use. Median difference=calculated median difference in MSI between RIC and control groups using non-parametric quantile regression. CIs and p values for interaction are computed with non-parametric bootstrapping (1000 replications). ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; MSI, myocardial salvage index; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning.

References

    1. Przyklenk K, Bauer B, Ovize M et al. . Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893–9. 10.1161/01.CIR.87.3.893
    1. Kharbanda RK, Mortensen UM, White PA et al. . Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881–3. 10.1161/01.CIR.0000043806.51912.9B
    1. Brevoord D, Kranke P, Kuijpers M et al. . Remote ischemic conditioning to protect against ischemia-reperfusion injury: a systematic review and meta-analysis. PLoS ONE 2012;7:e42179 10.1371/journal.pone.0042179
    1. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013;381:166–75. 10.1016/S0140-6736(12)60916-7
    1. Ferdinandy P, Hausenloy DJ, Heusch G et al. . Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014;66:1142–74. 10.1124/pr.113.008300
    1. McCafferty K, Forbes S, Thiemermann C et al. . The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech 2014;7:1321–33. 10.1242/dmm.016741
    1. Botker HE, Kharbanda R, Schmidt MR et al. . Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727–34. 10.1016/S0140-6736(09)62001-8
    1. Lang RM, Bierig M, Devereux RB et al. . Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108. 10.1016/j.euje.2005.12.014
    1. Grann AF, Erichsen R, Nielsen AG et al. . Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 2011;3:133–8. 10.2147/CLEP.S17901
    1. Gould W. sg11.1: Quantile regression with bootstrapped standard erros. Stata Technical Bulletin 9 1992:19–21.
    1. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014;34:509–15. 10.1161/ATVBAHA.113.300156
    1. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247–61. 10.1093/cvr/cvp033
    1. Moro L, Pedone C, Mondi A et al. . Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people. Atherosclerosis 2011;219:750–2. 10.1016/j.atherosclerosis.2011.08.046
    1. Schmidt MR, Stottrup NB, Michelsen MM et al. . Remote ischemic preconditioning impairs ventricular function and increases infarct size after prolonged ischemia in the isolated neonatal rabbit heart. J Thorac Cardiovasc Surg 2014;147:1049–55. 10.1016/j.jtcvs.2013.05.022
    1. D'Ascenzo F, Moretti C, Omede P et al. . Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention 2014;9:1463–71. 10.4244/EIJV9I12A244
    1. Xu X, Zhou Y, Luo S et al. . Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation. Angiology 2014;65:660–6. 10.1177/0003319713507332
    1. Jensen RV, Stottrup NB, Kristiansen SB et al. . Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol 2012;107:285 10.1007/s00395-012-0285-1
    1. Povlsen JA, Lofgren B, Dalgas C et al. . Protection against myocardial ischemia-reperfusion injury at onset of type 2 diabetes in Zucker diabetic fatty rats is associated with altered glucose oxidation. PLoS ONE 2013;8:e64093 10.1371/journal.pone.0064093
    1. Voucharas C, Lazou A, Triposkiadis F et al. . Remote preconditioning in normal and hypertrophic rat hearts. J Cardiothorac Surg 2011;6:34 10.1186/1749-8090-6-34
    1. Ludman A, Venugopal V, Yellon DM et al. . Statins and cardioprotection––more than just lipid lowering? Pharmacol Ther 2009;122:30–43. 10.1016/j.pharmthera.2009.01.002
    1. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005;45:1287–91. 10.1016/j.jacc.2005.01.021
    1. Ludman AJ, Hausenloy DJ, Babu G et al. . Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Res Cardiol 2011;106:1387–95. 10.1007/s00395-011-0209-5
    1. Yang JH, Hahn JY, Song YB et al. . Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2014;7:592–601. 10.1016/j.jcin.2013.12.206
    1. Zhou C, Liu Y, Yao Y et al. . Beta-blockers and volatile anesthetics may attenuate cardioprotection by remote preconditioning in adult cardiac surgery: a meta-analysis of 15 randomized trials. J Cardiothorac Vasc Anesth 2013;27:305–11. 10.1053/j.jvca.2012.09.028
    1. Ahnve S, Angelin B, Edhag O et al. . Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. J Intern Med 1989;226:297–301. 10.1111/j.1365-2796.1989.tb01399.x

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться